News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
198,466 Results
Type
Article (15241)
Company Profile (28)
Press Release (183192)
Multimedia
Podcasts (30)
Webinars (7)
Section
Business (54443)
Career Advice (696)
Deals (10038)
Drug Delivery (41)
Drug Development (29989)
Employer Resources (78)
FDA (5168)
Job Trends (4454)
News (100496)
Policy (8847)
Tag
2027 Pharm Country Standard (1)
Academia (1123)
Academic (1)
Accelerated approval (9)
Adcomms (9)
Allergies (55)
Alliances (15154)
ALS (62)
Alzheimer's disease (522)
Antibody-drug conjugate (ADC) (58)
Approvals (5301)
Artificial intelligence (124)
Autoimmune disease (36)
Automation (8)
Bankruptcy (74)
Best Places to Work (3510)
BIOSECURE Act (6)
Biosimilars (75)
Biotechnology (13)
Bladder cancer (45)
Brain cancer (19)
Breast cancer (194)
Cancer (1294)
Cardiovascular disease (155)
Career advice (587)
Career pathing (14)
CAR-T (81)
CDC (21)
Celiac Disease (2)
Cell therapy (194)
Cervical cancer (12)
Clinical research (26530)
Collaboration (394)
Company closure (1)
Compensation (55)
Complete response letters (10)
COVID-19 (1230)
CRISPR (22)
C-suite (223)
Cystic fibrosis (30)
Data (2112)
Denatured (21)
Depression (43)
Diabetes (185)
Diagnostics (1927)
Digital health (9)
Diversity (8)
Diversity, equity & inclusion (31)
Drug discovery (59)
Drug pricing (60)
Drug shortages (17)
Duchenne muscular dystrophy (75)
Earnings (16347)
Editorial (26)
Employer branding (9)
Employer resources (73)
Events (23706)
Executive appointments (289)
FDA (6069)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (392)
Gene editing (45)
Generative AI (13)
Gene therapy (172)
GLP-1 (369)
Government (1369)
Grass and pollen (3)
Guidances (114)
Healthcare (5783)
HIV (32)
Huntington's disease (12)
IgA nephropathy (21)
Immunology and inflammation (64)
Immuno-oncology (16)
Indications (26)
Infectious disease (1322)
Inflammatory bowel disease (66)
Inflation Reduction Act (6)
Influenza (36)
Intellectual property (30)
Interviews (110)
IPO (3715)
IRA (22)
Job creations (1049)
Job search strategy (507)
JPM (22)
Kidney cancer (4)
Labor market (21)
Layoffs (140)
Leadership (17)
Legal (1907)
Liver cancer (28)
Longevity (2)
Lung cancer (141)
Lymphoma (111)
Machine learning (8)
Management (25)
Manufacturing (186)
MASH (68)
Medical device (3506)
Medtech (3525)
Mergers & acquisitions (6623)
Metabolic disorders (427)
Multiple sclerosis (75)
NASH (15)
Neurodegenerative disease (82)
Neuropsychiatric disorders (20)
Neuroscience (921)
Neurotech (1)
NextGen: Class of 2026 (2184)
Non-profit (1724)
Now hiring (5)
Obesity (174)
Opinion (87)
Ovarian cancer (48)
Pain (56)
Pancreatic cancer (47)
Parkinson's disease (96)
Partnered (15)
Patents (45)
Patient recruitment (120)
Peanut (20)
People (20365)
Pharmaceutical (11)
Pharmacy benefit managers (11)
Phase 1 (6058)
Phase 2 (11415)
Phase 3 (10726)
Pipeline (1370)
Policy (105)
Postmarket research (1238)
Preclinical (2182)
Press Release (34)
Prostate cancer (83)
Psychedelics (17)
Radiopharmaceuticals (69)
Rare diseases (240)
Real estate (1587)
Recruiting (27)
Regulatory (6915)
Reports (14)
Research institute (969)
Resumes & cover letters (110)
Rett syndrome (2)
RNA editing (2)
RSV (31)
Schizophrenia (43)
Series A (80)
Series B (56)
Service/supplier (2)
Sickle cell disease (27)
Special edition (3)
Spinal muscular atrophy (67)
Sponsored (10)
Startups (1337)
Stomach cancer (5)
Supply chain (24)
Tariffs (18)
The Weekly (9)
Vaccines (422)
Venture capital (29)
Weight loss (126)
Women's health (23)
Worklife (8)
Date
Today (1)
Last 7 days (152)
Last 30 days (487)
Last 365 days (7520)
2026 (626)
2025 (7755)
2024 (8884)
2023 (10268)
2022 (14507)
2021 (15929)
2020 (15363)
2019 (14604)
2018 (11304)
2017 (10271)
2016 (9904)
2015 (11857)
2014 (8123)
2013 (6419)
2012 (6902)
2011 (7412)
2010 (6475)
Location
Africa (319)
Alabama (9)
Alaska (4)
Arizona (68)
Arkansas (2)
Asia (13691)
Australia (2695)
California (2380)
Canada (631)
China (367)
Colorado (92)
Connecticut (79)
Delaware (101)
Europe (37897)
Florida (364)
Georgia (112)
Idaho (15)
Illinois (256)
India (20)
Indiana (151)
Iowa (3)
Japan (181)
Kansas (39)
Kentucky (15)
Louisiana (11)
Maine (12)
Maryland (350)
Massachusetts (1634)
Michigan (55)
Minnesota (149)
Missouri (33)
Montana (6)
Nebraska (13)
Nevada (33)
New Hampshire (15)
New Jersey (856)
New Mexico (7)
New York (771)
North Carolina (316)
Northern California (1162)
Ohio (77)
Oklahoma (3)
Oregon (4)
Pennsylvania (545)
Puerto Rico (4)
Rhode Island (4)
South America (419)
South Carolina (11)
Southern California (926)
Tennessee (35)
Texas (300)
United States (9010)
Utah (60)
Virginia (52)
Washington D.C. (9)
Washington State (232)
Wisconsin (23)
Wyoming (2)
198,466 Results for "smiths group".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Insights
From Nuclear Winter to Renewal: Biotech Investing for 2026
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Maha Katabi, general partner at Sofinnova Investments and Andrew Lam, managing director, head of Biotech Private Equity at Ally Bridge Group, about how M &A dynamics, dealmaking and global partnerships are reshaping portfolio valuations and paths to growth in 2026.
January 8, 2026
·
1 min read
·
Jennifer Smith-Parker
Insights
Programmable RNA 2.0: Beyond the First mRNA Revolution
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklund, CEO of Circio and Jacob Becraft, Co-founder and CEO of Strand Therapeutics. They discuss how post-COVID, emerging platforms like circular and logic circuit RNA are expanding the field’s therapeutic horizons.
February 5, 2026
·
1 min read
·
Jennifer Smith-Parker
FDA
New Approach Methodologies: Redefining Animal Testing Alternatives
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Stacey Adam, PhD, Vice President of Science Partnerships at the Foundation for the National Institutes of Health and Patrick Smith, Senior Vice President, Translational Science at Certara, to discuss the latest regulatory news and the future for new approach methologies (NAMs) development.
December 4, 2025
·
1 min read
·
BioSpace Insights
Press Releases
Smith+Nephew completes acquisition of Integrity Orthopaedics; establishes unrivalled portfolio for shoulder repair
January 22, 2026
·
6 min read
Deals
Inside the 2026 Biotech Landscape: Innovation, Investment and Global Momentum
In this episode of Denatured, Jennifer Smith-Parker speaks to Kenneth Galbraith,
CEO of Zymeworks and Josh Smiley, president and COO of Zai Lab, about how renewed confidence is driving biotech entering 2026.
December 18, 2025
·
1 min read
·
BioSpace Insights
Insights
Biotech’s New Cycle, JPM Deal Hype and Where Alpha Still Hides
In this episode of Denatured, Jennifer C. Smith-Parker speaks with RTW’s Rod Wong and Stephanie Sirota how shifting JPM deal timing masks record M&A potential; why oncology, obesity, psychedelics, and neuroscience are attracting fresh capital; and how “alpha stacking” shapes their investment edge in an age of chronic uncertainty. They cover topics discussed in RTW’s new book, “Innovation is the Best Medicine.”
January 29, 2026
·
1 min read
·
Jennifer Smith-Parker
Press Releases
Secura Bio Announces Participation in Gilmartin Group’s 2026 Corporate Access Event in San Francisco
December 24, 2025
·
4 min read
IN PARTNERSHIP WITH ANAPTYSBIO
Beyond the Gluten-Free Diet: A New Era in Celiac Disease Treatment
In this episode of Denatured presented by AnaptysBio, Jennifer Smith-Parker speaks to Dr. Joe Murray, Mayo Clinic; Marilyn Geller, the Celiac Disease Foundation; and Dr. Paul Lizzul, AnaptysBio, about the challenges and opportunities facing celiac disease treatment.
December 11, 2025
·
1 min read
·
Jennifer Smith-Parker
Press Releases
UPSHER-SMITH LAUNCHES KYMBEE™ (DEFLAZACORT) TABLETS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
December 2, 2025
·
6 min read
Press Releases
Allergy Research Group Announces Peer-Reviewed Publication Advancing Thyroid and Endocrine Integration Science
February 5, 2026
·
2 min read
1 of 19,847
Next